Growth Factors and Their Roles in Multiple Sclerosis Risk

• Published in: Frontiers in immunology Vol. 12; p. 768682
• Main Authors: Lu, Hui, Wu, Peng-Fei, Ma, Deng-Lei, Zhang, Wan, Sun, Meichen
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 21.10.2021
• Subjects: Adult; Aged; Female; fibroblast growth factor 23; Fibroblast Growth Factor-23 - physiology; genetic epidemiology; Genome-Wide Association Study; Growth Differentiation Factor 15 - physiology; growth factors; Humans; Immunology; Insulin-Like Growth Factor Binding Protein 3 - physiology; Intercellular Signaling Peptides and Proteins - blood; Intercellular Signaling Peptides and Proteins - physiology; Male; Mendelian randomization; Mendelian Randomization Analysis; Middle Aged; multiple sclerosis; Multiple Sclerosis - etiology; Vascular Endothelial Growth Factor A - physiology; Mendelian randomization; growth factors; fibroblast growth factor 23; multiple sclerosis; genetic epidemiology
• DOI: 10.3389/fimmu.2021.768682
• ISSN: 1664-3224

Previous studies have suggested essential roles of growth factors on the risk of Multiple Sclerosis (MS), but it remains undefined whether the effects are causal. We applied Mendelian randomization (MR) approaches to disentangle the causal relationship between genetically predicted circulating levels of growth factors and the risk of MS. Genetic instrumental variables for fibroblast growth factor (FGF) 23, growth differentiation factor 15 (GDF15), insulin growth factor 1 (IGF1), insulin-like growth factor binding proteins 3 (IGFBP3) and vascular endothelial growth factor (VEGF) were obtained from up-to-date genome-wide association studies (GWAS). Summary-level statistics of MS were obtained from the International Multiple Sclerosis Genetics Consortium, incorporating 14,802 subjects with MS and 26,703 healthy controls of European ancestry. Inverse-variance weighted (IVW) MR was used as the primary method and multiple sensitivity analyses were employed in this study. Genetically predicted circulating levels of FGF23 were associated with risk of MS. The odds ratio (OR) of IVW was 0.63 (95% confidence interval [CI], 0.49-0.82; < 0.001) per one standard deviation increase in circulating FGF23 levels. Weighted median estimators also suggested FGF23 associated with lower MS risk (OR = 0.67; 95% CI, 0.51-0.87; = 0.003). While MR-Egger approach provided no evidence of horizontal pleiotropy (intercept = -0.003, = 0.95). Results of IVW methods provided no evidence for causal roles of GDF1, IGF1, IGFBP3 and VEGF on MS risks, and additional sensitivity analyses confirmed the robustness of these null findings. Our results implied a causal relationship between FGF23 and the risk of MS. Further studies are warranted to confirm FGF23 as a genetically valid target for MS.